US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

ATNM Actinium Pharmaceuticals Inc

8.46

0.68 (8.74%)

Última actualización: 12:51:49

Retrasado por 15 minutos

Form EFFECT - Notice of Effectiveness

Actinium Pharmaceuticals (AMEX:ATNM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Actinium Pharmaceuticals.

Actinium Pharmaceuticals (AMEX:ATNM)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Actinium Pharmaceuticals.

Noticias sobre Actinium Pharmaceuticals Inc ATNM

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Jueves 18 de Abril 2024 (2 semanas hace) • PR Newswire (US)

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual
Lunes 1 de Abril 2024 (1 mes hace) • PR Newswire (US)

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Martes 26 de Marzo 2024 (1 mes hace) • PR Newswire (US)

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Lunes 11 de Marzo 2024 (2 meses hace) • PR Newswire (US)

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT
Lunes 26 de Febrero 2024 (2 meses hace) • PR Newswire (US)

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB
Viernes 23 de Febrero 2024 (2 meses hace) • PR Newswire (US)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Viernes 9 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Lunes 5 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
Viernes 2 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Martes 2 de Enero 2024 (4 meses hace) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 29 de Diciembre 2023 (4 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 29 de Diciembre 2023 (4 meses hace) • Edgar (US Regulatory)

Más de Actinium Pharmaceuticals Inc Artículos de Noticias

Verizon Communications

Financial Select Sector

Bank of America

Energy Select Sector SPDR

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones